|
August 4-6, 2009
(August 4 pre-conference workshop*, August 6-5 main conference)
Understanding the Physiological Relevance of Targets with Novel Technologies and Approaches
The conference attempts to address the link between targets and diseases through the understanding of the physiological relevance of targets in context, to select the right targets to move forward for drug development. Proven or novel technologies, approaches and strategies for target validation will be explored and case studies of targets in preclinical or clinical development will be presented to illustrate the clinical relevance and validation of the targets.
Why You Should Attend:
- The ONE event that looks specifically at how companies are linking targets to disease more effectively, through the use of various innovative tools and ultimately showing proof-of-concept in the clinic
- Learn about the effectiveness of the various tools and approaches, from genomics, proteomics, metabolomics to systems biology and RNAi, from in vivo and computational approaches to cell- and tissue-based screening methods.
- Hear case studies of targets for oncology, diabetes and inflammation in the clinic
Conference Highlights
Conference Keynote
Build-Couple-Pair Strategy for Diversity-Oriented Synthesis Yields a Unique Compound Collection for Probe Development and Drug Discovery
Michael Foley, Ph.D.
Director, Chemical Biology Platform
Broad Institute at MIT and Harvard University
2 Optional Pre-Conference Workshops to Choose from
I: RNAi in Practice
II: Label-Free Assays
Plenary Keynote
Global Pharma Innovator: Daiichi Sankyo's Challenge to Build a Competitive Pharmaceutical Company in the Global Market
Takashi Shoda
President and CEO
Daiichi Sankyo Co., Ltd., Japan
Conference Sessions Include:
- Genomics, Proteomics and Systems Biology Approaches to Finding the Right Target
- Antibody-Based Approaches
- In Vivo and Computational Approaches
- RNAi Approaches To Target Validation
- High Content / High Throughput Screening & Assay Approaches
- Case Studies to Illustrate Preclinical To Clinical Translation - Ensuring the Ultimate Clinical Success Of Your Targets
Scientific Advisory Board
Charles Kunsch, Ph.D., Vice President, Biology, AtheroGenics, Inc.
Lisa Minor, Ph.D., Principal Scientist, Johnson & Johnson Pharmaceutical R&D
Isabelle Morize, Ph.D., Head of Drug Design 1, Chemical & Analytical Sciences, Sanofi-Aventis
Ulrik Nielsen, Ph.D., Senior Vice President, Research, Merrimack Pharmaceuticals
Daniel Sipes, Head Operations Screening, G N F
Edward Suh, Ph.D., Director, Integrated Discovery Technologies, Eisai Research Institute
|
